Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
There is a challenge related to prostate and many other cancers that cancer cells form resistance to treatments as the disease progresses.
However, these resistance mechanisms are not yet fully understood.
A new study by the University of Eastern Finland found that inflammation-promoting immune cells, M1 macrophages, can transform cancer cells into stem-like cells and thus immune to treatment.
The results were published in OncoImmunology journal.
The study examined the impact of factors promoting inflammation in a tumour microenvironment on the progression of prostate cancer.
Researchers focused particularly on the role of M1 and M2 macrophages in the tumour microenvironment .
Macrophages are immune cells whose large number in the tumour area is often a sign of poor prognosis in relation to prostate cancer.
The study found that pro-inflammatory macrophages (M1) increase the stem cell traits of cancer cells and weaken the androgen response.
"We found that pro-inflammatory M1 macrophages secreted factors that increased the expression of stem cell markers such as NANOG, KLF4, SOX2 and CD44 in prostate cancer cells.
Based on our research, it seems that inflammatory tumour microenvironment promotes the transformation of prostate cancer cells into a stem cell-like state where they are resistant to traditional therapies," says Doctoral Researcher Kirsi Kainulainen.
The results help us understand how immune response affects the progression of prostate cancer and resistance to treatments.
Observations on the effects of immune cells on the transformation capacity of cancer cells may open up new treatment opportunities for prostate cancer.
The study was carried out by Senior University Lecturer Sanna Pasonen-Seppänen and Research Director Kirsi Ketola at the University of Eastern Finland's Institute of Biomedicine.
The study has been supported by the Academy of Finland, the Sigrid Juselius Foundation, the Cancer Foundation Finland, the North Savo Cancer Association, the Finnish Cultural Foundation, the Northern Savo Cultural Foundation, the Paavo Koistinen Foundation and the Kuopio University Foundation.
Source: University of Eastern Finland
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.